FibroGen, Inc. (0IL8.L)
USD 0.34
(-1.86%)
USD 0.34
(-1.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -261.4 Million USD | 8.33% |
| 2022 | -282.82 Million USD | 1.98% |
| 2021 | -274.79 Million USD | -54.85% |
| 2020 | -164.28 Million USD | -152.59% |
| 2019 | -52.31 Million USD | 1.81% |
| 2018 | -68.56 Million USD | 35.34% |
| 2017 | -104.74 Million USD | -158.25% |
| 2016 | -44.98 Million USD | 39.62% |
| 2015 | -68.82 Million USD | -69.61% |
| 2014 | -43.92 Million USD | -5310.68% |
| 2013 | 843 Thousand USD | 104.95% |
| 2012 | -17.04 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -10.13 Million USD | 63.37% |
| 2024 Q1 | -30.24 Million USD | 44.46% |
| 2023 Q3 | -46.58 Million USD | 45.45% |
| 2023 Q4 | -52.32 Million USD | -12.32% |
| 2023 Q1 | -75.05 Million USD | -20.02% |
| 2023 Q2 | -85.39 Million USD | -13.78% |
| 2023 FY | - USD | 8.33% |
| 2022 Q4 | -62.53 Million USD | 29.87% |
| 2022 FY | - USD | 1.98% |
| 2022 Q3 | -89.18 Million USD | -26.72% |
| 2022 Q2 | -70.37 Million USD | -16.5% |
| 2022 Q1 | -60.4 Million USD | 54.99% |
| 2021 FY | - USD | -54.85% |
| 2021 Q2 | -129.53 Million USD | -97.65% |
| 2021 Q4 | -134.19 Million USD | -350.53% |
| 2021 Q3 | 53.56 Million USD | 141.35% |
| 2021 Q1 | -65.54 Million USD | -13.52% |
| 2020 FY | - USD | -152.59% |
| 2020 Q1 | -77.9 Million USD | 20.0% |
| 2020 Q2 | -78.97 Million USD | -1.36% |
| 2020 Q3 | 39.37 Million USD | 149.86% |
| 2020 Q4 | -57.73 Million USD | -246.64% |
| 2019 Q4 | -97.38 Million USD | -127.06% |
| 2019 FY | - USD | 1.81% |
| 2019 Q3 | -42.88 Million USD | -135.07% |
| 2019 Q2 | 122.29 Million USD | 410.76% |
| 2019 Q1 | -39.35 Million USD | -266.11% |
| 2018 Q3 | -38.08 Million USD | -100.11% |
| 2018 Q4 | 23.69 Million USD | 162.21% |
| 2018 Q1 | -37 Million USD | -83.58% |
| 2018 Q2 | -19.03 Million USD | 48.58% |
| 2018 FY | - USD | 35.34% |
| 2017 FY | - USD | -158.25% |
| 2017 Q3 | -33.4 Million USD | -15.85% |
| 2017 Q1 | -29.2 Million USD | 1.16% |
| 2017 Q2 | -28.83 Million USD | 1.27% |
| 2017 Q4 | -20.16 Million USD | 39.64% |
| 2016 FY | - USD | 39.62% |
| 2016 Q4 | -29.54 Million USD | -49.79% |
| 2016 Q3 | -19.72 Million USD | -170.07% |
| 2016 Q2 | 28.14 Million USD | 217.93% |
| 2016 Q1 | -23.86 Million USD | 49.08% |
| 2015 FY | - USD | -69.61% |
| 2015 Q4 | -46.87 Million USD | -14.63% |
| 2015 Q3 | -40.89 Million USD | -166.56% |
| 2015 Q2 | 61.43 Million USD | 244.57% |
| 2015 Q1 | -42.49 Million USD | 8.59% |
| 2014 Q2 | 50.48 Million USD | 500.63% |
| 2014 Q4 | -46.48 Million USD | -31.6% |
| 2014 Q3 | -35.32 Million USD | -169.97% |
| 2014 FY | - USD | -5310.68% |
| 2014 Q1 | -12.6 Million USD | 45.0% |
| 2013 Q1 | -15.36 Million USD | 0.0% |
| 2013 Q3 | 43.29 Million USD | 801.39% |
| 2013 Q2 | -6.17 Million USD | 59.84% |
| 2013 Q4 | -22.91 Million USD | -152.93% |
| 2013 FY | - USD | 104.95% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | -3.281% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -416.897% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -197.102% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 24.332% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 1.726% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -122.189% |
| Imunon, Inc. | -20.78 Million USD | -1157.827% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2804.376% |
| Editas Medicine, Inc. | -163.11 Million USD | -60.256% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 41.782% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -624.475% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 162.823% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 40.481% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 366.029% |
| Verastem, Inc. | -83.16 Million USD | -214.317% |
| Zoetis Inc. | 3.68 Billion USD | 107.094% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 105.676% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -198.998% |
| Homology Medicines, Inc. | -47.75 Million USD | -447.376% |
| Nektar Therapeutics | -243.1 Million USD | -7.527% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -159.261% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -601.137% |
| Perrigo Company plc | 646.2 Million USD | 140.453% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -74.145% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 97.682% |
| Illumina, Inc. | -608 Million USD | 57.006% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.42% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 108.028% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -151.855% |
| Waters Corporation | 1.02 Billion USD | 125.572% |
| Biogen Inc. | 2.37 Billion USD | 110.997% |
| Evolus, Inc. | -41.81 Million USD | -525.221% |
| Adicet Bio, Inc. | -136.53 Million USD | -91.456% |
| bluebird bio, Inc. | -167.16 Million USD | -56.379% |
| Geron Corporation | -174.78 Million USD | -49.561% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -14.591% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -183.892% |
| Myriad Genetics, Inc. | -67.8 Million USD | -285.553% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 48.371% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 122.457% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -488.264% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 184.247% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 105.617% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 115.588% |
| OPKO Health, Inc. | -65.51 Million USD | -298.994% |
| Exelixis, Inc. | 196.6 Million USD | 232.962% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 341.318% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -368.837% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -16.185% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -13.649% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 157.84% |
| Blueprint Medicines Corporation | -474.61 Million USD | 44.922% |
| Insmed Incorporated | -654.73 Million USD | 60.075% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1101.552% |
| Incyte Corporation | 919.42 Million USD | 128.431% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 48.267% |